Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

In Q3, the top 10 TV ad spenders poured a combined $544.8 million into airing their commercials, according to data shared ...

Apogee Therapeutics, Inc. targets atopic dermatitis with APG777, aiming to outperform Dupixent. Learn more about APGE stock ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...

Sanofi Q3 sales beat estimates on strong Dupixent and new drug demand; reaffirms 2025 outlook with double-digit EPS growth ...

Bullous pemphigoid (BP) is an autoimmune disorder that mainly affects older adults. The condition causes your immune system to attack proteins that hold the layers of your skin together. This damages ...

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...